2. Academic Validation
  3. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

  • Nat Biomed Eng. 2019 Apr;3(4):306-317. doi: 10.1038/s41551-019-0375-6.
Han Yao 1,  Jiang Lan 2,  Chushu Li 1,  Hubing Shi 2,  Jean-Philippe Brosseau 3,  Huanbin Wang 1,  Haojie Lu 4,  Caiyun Fang 4,  Yao Zhang 1,  Lunxi Liang 1 5,  Xiaolin Zhou 6,  Chaojun Wang 7,  Yu Xue 8,  Yun Cui 1,  Jie Xu 9
Affiliations

Affiliations

  • 1 State Key Laboratory for Oncogenes and Related Genes, Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • 2 Laboratory of Tumor Targeted and Immune Therapy, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China.
  • 3 Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • 4 Department of Chemistry and Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
  • 5 Department of Gastroenterology, Changsha Central Hospital, Changsha, China.
  • 6 Department of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China.
  • 7 Urology Department, The First Affiliated Hospital of Zhejiang University, Zhejiang, China.
  • 8 Department of Bioinformatics & Systems Biology, Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.
  • 9 State Key Laboratory for Oncogenes and Related Genes, Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. [email protected].
PMID: 30952982 DOI: 10.1038/s41551-019-0375-6
Abstract

Checkpoint blockade therapy targeting the programmed-death ligand 1 (PD-L1) and its receptor programmed cell death 1 promotes T-cell-mediated immunosurveillance against tumours, and has been associated with marked clinical benefit in Cancer patients. Antibodies against PD-L1 function by blocking PD-L1 on the cell surface, but intracellular storage of PD-L1 and its active redistribution to the cell membrane can minimize the therapeutic benefits, which highlights the importance of targeting PD-L1 throughout the whole cell. Here, we show that PD-L1 is palmitoylated in its cytoplasmic domain, and that this lipid modification stabilizes PD-L1 by blocking its ubiquitination, consequently suppressing PD-L1 degradation by lysosomes. We identified palmitoyltransferase ZDHHC3 (DHHC3) as the main acetyltransferase required for the palmitoylation of PD-L1, and show that the inhibition of PD-L1 palmitoylation via 2-bromopalmitate, or the silencing of DHHC3, activates antitumour immunity in vitro and in mice bearing MC38 tumour cells. We also designed a competitive inhibitor of PD-L1 palmitoylation that decreases PD-L1 expression in tumour cells to enhance T-cell immunity against the tumours. These findings suggest new strategies for overcoming PD-L1-mediated immune evasion in Cancer.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-100736
    99.96%, APT1/LYPLA1 Inhibitor